Kendomycin Cytotoxicity against Bacterial, Fungal, and Mammalian Cells Is Due to Cation Chelation.


Journal

Journal of natural products
ISSN: 1520-6025
Titre abrégé: J Nat Prod
Pays: United States
ID NLM: 7906882

Informations de publication

Date de publication:
24 04 2020
Historique:
pubmed: 18 3 2020
medline: 22 6 2021
entrez: 18 3 2020
Statut: ppublish

Résumé

Kendomycin is a small-molecule natural product that has gained significant attention due to reported cytotoxicity against pathogenic bacteria and fungi as well as a number of cancer cell lines. Despite significant biomedical interest and attempts to reveal its mechanism of action, the cellular target of kendomycin remains disputed. Herein it is shown that kendomycin induces cellular responses indicative of cation stress comparable to the effects of established iron chelators. Furthermore, addition of excess iron and copper attenuated kendomycin cytotoxicity in bacteria, yeast, and mammalian cells. Finally, NMR analysis demonstrated a direct interaction with cations, corroborating a close link between the observed kendomycin polypharmacology across different species and modulation of iron and/or copper levels.

Identifiants

pubmed: 32182062
doi: 10.1021/acs.jnatprod.9b00826
pmc: PMC7497661
doi:

Substances chimiques

Anti-Bacterial Agents 0
Antibiotics, Antineoplastic 0
Antifungal Agents 0
Cations 0
Chelating Agents 0
Leupeptins 0
kendomycin 0
Rifabutin 1W306TDA6S
Copper 789U1901C5
Iron E1UOL152H7
benzyloxycarbonylleucyl-leucyl-leucine aldehyde RF1P63GW3K

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

965-971

Références

J Cell Sci. 2015 Mar 15;128(6):1217-29
pubmed: 25616894
Nature. 2012 Mar 28;483(7391):603-7
pubmed: 22460905
Expert Opin Investig Drugs. 2005 Nov;14(11):1419-34
pubmed: 16255680
J Cell Biochem. 2012 Aug;113(8):2567-75
pubmed: 22415943
Development. 2010 Aug 1;137(15):2587-96
pubmed: 20627962
J Mol Biol. 2014 Sep 9;426(18):3108-3117
pubmed: 25038530
J Biol Inorg Chem. 2008 Nov;13(8):1205-18
pubmed: 18604568
Chembiochem. 2007 Jul 23;8(11):1261-72
pubmed: 17592829
PLoS Genet. 2016 Nov 17;12(11):e1006374
pubmed: 27855158
Sci Rep. 2017 Feb 16;7:42728
pubmed: 28205648
Microbiol Res. 2014 Feb-Mar;169(2-3):107-20
pubmed: 24360837
J Inorg Biochem. 2014 Nov;140:104-10
pubmed: 25105866
Mol Biol Cell. 2016 Jan 15;27(2):349-59
pubmed: 26564796
Metallomics. 2013 Aug;5(8):1068-75
pubmed: 23832094
J Appl Microbiol. 2018 May;124(5):1032-1046
pubmed: 29280540
Proc Natl Acad Sci U S A. 2004 Jan 20;101(3):793-8
pubmed: 14718668
Chembiochem. 2008 Nov 3;9(16):2711-21
pubmed: 18972512
BMC Complement Altern Med. 2017 Aug 17;17(1):412
pubmed: 28818104
J Biol Inorg Chem. 2017 Oct;22(7):1075-1087
pubmed: 28836015
J Biol Chem. 1995 Jul 21;270(29):17442-56
pubmed: 7615550
Science. 2014 Apr 11;344(6180):208-11
pubmed: 24723613
Biochim Biophys Acta Gen Subj. 2017 May;1861(5 Pt A):995-999
pubmed: 28219722
J Antibiot (Tokyo). 2012 Feb;65(2):103-8
pubmed: 22167156
Worm. 2013 Jul 1;2(3):e25081
pubmed: 24778934
Angew Chem Int Ed Engl. 2015 Aug 24;54(35):10149-54
pubmed: 26179970
PLoS One. 2016 Jan 21;11(1):e0146165
pubmed: 26795276
Autophagy. 2017 Aug 3;13(8):1465-1466
pubmed: 28613094
J Am Chem Soc. 2004 Nov 17;126(45):14720-1
pubmed: 15535687
Mol Cell Biol. 2005 Aug;25(15):6760-71
pubmed: 16024809
Cell Chem Biol. 2016 May 19;23(5):561-566
pubmed: 27203376
Diseases. 2016 Aug 01;4(3):
pubmed: 28933408

Auteurs

Dale Tranter (D)

Institute of Biotechnology, University of Helsinki, Helsinki, 00014, Finland.

Ireos Filipuzzi (I)

Novartis Institutes for BioMedical Research, 4056 Basel, Switzerland.

Thomas Lochmann (T)

Novartis Institutes for BioMedical Research, 4056 Basel, Switzerland.

Britta Knapp (B)

Novartis Institutes for BioMedical Research, 4056 Basel, Switzerland.

Juho Kellosalo (J)

Institute of Biotechnology, University of Helsinki, Helsinki, 00014, Finland.

David Estoppey (D)

Novartis Institutes for BioMedical Research, 4056 Basel, Switzerland.

Dominik Pistorius (D)

Novartis Institutes for BioMedical Research, 4056 Basel, Switzerland.

Axel Meissner (A)

Novartis Institutes for BioMedical Research, 4056 Basel, Switzerland.

Ville O Paavilainen (VO)

Institute of Biotechnology, University of Helsinki, Helsinki, 00014, Finland.

Dominic Hoepfner (D)

Novartis Institutes for BioMedical Research, 4056 Basel, Switzerland.

Articles similaires

Vancomycin-associated DRESS demonstrates delay in AST abnormalities.

Ahmed Hussein, Kateri L Schoettinger, Jourdan Hydol-Smith et al.
1.00
Humans Drug Hypersensitivity Syndrome Vancomycin Female Male
Humans Arthroplasty, Replacement, Elbow Prosthesis-Related Infections Debridement Anti-Bacterial Agents
Populus Soil Microbiology Soil Microbiota Fungi
Aerosols Humans Decontamination Air Microbiology Masks

Classifications MeSH